von Karstedt, Silvia http://orcid.org/0000-0002-7816-5919
Walczak, Henning
Funding for this research was provided by:
Deutsche Krebshilfe (701125509)
Deutsche Forschungsgemeinschaft (432038712, SFB1399, SFB1403, SFB1399)
Bundesministerium für Bildung und Forschung (01ZX1901A)
Wellcome Trust (214342/Z/18/Z)
Cancer Research UK (A27323)
Article History
Received: 22 January 2020
Revised: 28 February 2020
Accepted: 3 March 2020
First Online: 17 March 2020
Conflict of interest
: S.v.K. and H.W. are named inventors on one (S.v.K.) and two (H.W.) patent applications, respectively, covering some of the therapeutic concepts discussed here. H. W. is founder and shareholder of Apogenix AG, a biopharmaceutical company which develops a biotherapeutic inhibitor of CD95L.